Skip to main content
Journal cover image

6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias.

Publication ,  Journal Article
Armaganijan, LV; Staico, R; Moreira, DAR; Lopes, RD; Medeiros, PTJ; Habib, R; Melo Neto, J; Katz, M; Armaganijan, D; Sousa, AGMR; Mahfoud, F ...
Published in: JACC Cardiovasc Interv
June 2015

OBJECTIVES: This study aimed to assess 6-month outcomes in patients with implantable cardioverter-defibrillators (ICDs) undergoing renal sympathetic denervation (RSD) for refractory ventricular arrhythmias (VAs). BACKGROUND: ICDs are generally indicated for patients at high risk of malignant VAs. Sympathetic hyperactivity plays a critical role in the development, maintenance, and aggravation of VAs. METHODS: A total of 10 patients with refractory VA underwent RSD. Underlying conditions were Chagas disease (n = 6), nonischemic dilated cardiomyopathy (n = 2), and ischemic cardiomyopathy (n = 2). Information on the number of ventricular tachycardia (VT)/ventricular fibrillation (VF) episodes and device therapies (antitachycardia pacing/shocks) in the previous 6 months as well as 1 and 6 months post-treatment was obtained from ICD interrogation. RESULTS: The median number of VT/VF episodes/antitachycardia pacing/shocks 6 months before RSD was 28.5 (range 1 to 106)/20.5 (range 0 to 52)/8 (range 0 to 88), respectively, and was reduced to 1 (range 0 to 17)/0 (range 0 to 7)/0 (range 0 to 3) at 1 month and 0 (range 0 to 9)/0 (range 0 to 7)/0 (range 0 to 3) at 6 months afterward, respectively. There were no major procedure-related complications. Two patients experienced sustained VT within the first week; in both cases, no further episodes occurred during follow-up. Two patients were nonresponders: 1 with persistent idioventricular rhythm and 1 with multiple renal arteries and incomplete ablation. Three patients died during follow-up. None of the deaths was attributed to VA. CONCLUSIONS: In patients with ICDs and refractory VAs, RSD was associated with reduced arrhythmic burden with no procedure-related complications. Randomized controlled trials investigating RSD for treatment of refractory VAs in patients with increased sympathetic activity are needed.

Duke Scholars

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

June 2015

Volume

8

Issue

7

Start / End Page

984 / 990

Location

United States

Related Subject Headings

  • Ventricular Fibrillation
  • Treatment Outcome
  • Time Factors
  • Tachycardia, Ventricular
  • Sympathectomy
  • Risk Factors
  • Renal Artery
  • Prospective Studies
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armaganijan, L. V., Staico, R., Moreira, D. A. R., Lopes, R. D., Medeiros, P. T. J., Habib, R., … Abizaid, A. (2015). 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv, 8(7), 984–990. https://doi.org/10.1016/j.jcin.2015.03.012
Armaganijan, Luciana V., Rodolfo Staico, Dalmo A. R. Moreira, Renato D. Lopes, Paulo T. J. Medeiros, Ricardo Habib, Jônatas Melo Neto, et al. “6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias.JACC Cardiovasc Interv 8, no. 7 (June 2015): 984–90. https://doi.org/10.1016/j.jcin.2015.03.012.
Armaganijan LV, Staico R, Moreira DAR, Lopes RD, Medeiros PTJ, Habib R, et al. 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv. 2015 Jun;8(7):984–90.
Armaganijan, Luciana V., et al. “6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias.JACC Cardiovasc Interv, vol. 8, no. 7, June 2015, pp. 984–90. Pubmed, doi:10.1016/j.jcin.2015.03.012.
Armaganijan LV, Staico R, Moreira DAR, Lopes RD, Medeiros PTJ, Habib R, Melo Neto J, Katz M, Armaganijan D, Sousa AGMR, Mahfoud F, Abizaid A. 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv. 2015 Jun;8(7):984–990.
Journal cover image

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

June 2015

Volume

8

Issue

7

Start / End Page

984 / 990

Location

United States

Related Subject Headings

  • Ventricular Fibrillation
  • Treatment Outcome
  • Time Factors
  • Tachycardia, Ventricular
  • Sympathectomy
  • Risk Factors
  • Renal Artery
  • Prospective Studies
  • Middle Aged
  • Male